Cookies on this site

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Marie Pust

Marie Pust has joined the Kennedy Institute as a Kennedy Trust for Rheumatology Research (KTRR) Group Leader in Microbiome Studies. Describing herself as ‘a microbial ecologist who is interested in integrating ecological principles in translational microbiome research through clinical collaborations’, she hopes an interdisciplinary approach will deliver meaningful benefits for patients. ‘After decades of microbiome research, there is still a huge gap between the research we are doing and the outcomes that actually reach patients,’ she said.

Marie began her research career in Germany, where her PhD in Professor Burkhard Tümmler's group, supported by the Studienstiftung, focused on the development of the airway microbiome in infants with chronic lung diseases. During that time, she became increasingly interested in how microbial communities function beyond gene content alone. Bacterial species with near-identical gene pools can behave very differently, and other functional genome layers, such as spatial architecture and regulatory mechanisms, help explain why.

To explore these functional layers at scale, Marie needed larger multi-omics datasets and clinical cohorts. This brought her to Harvard, where she spent four years as a postdoc with Professor Ramnik Xavier, an expert in inflammatory bowel disease (IBD) and the gut microbiome. Supported by a DFG Walter Benjamin fellowship, she developed software to study the transcriptional dynamics of the IBD gut, identifying microbial antisense RNAs as candidate biomarkers for inflammatory activity in the gut. 

At the Kennedy Institute, Marie will build her research group within the Oxford Centre for Microbiome Studies (OCMS). Her group will explore how the gut ecosystem, with its resources and stressors, shapes bacterial function in patients with IBD, how that function is encoded and regulated across strains, and how it feeds back on host interactions. ‘One problem with how we think about the microbiome is the tendency to divide bacteria into “good” and “bad”,’ she explained. ‘In reality, what bacteria do depend on both their functional potential and their environment. A ‘good’ bacterium transferred from a healthy gut into a diseased ecosystem, with other resources and stressors, may behave very differently. Equally, strains with similar gene content may perform different functions in the same ecosystem because the same genes can be regulated differently.’

By understanding how the gut environment and bacterial strains encode function, Marie hopes to lay the groundwork for personalised microbiome therapies.

Jethro Johnson, Deputy Director of the Oxford Centre for Microbiome Studies said: ‘It’s fantastic to have Marie join us here at the Kennedy Institute. Her vision for understanding and tackling the complexities of the human microbiome is unique. The opportunity to work with her as part of the OCMS is really exciting, and promises to take us to new places in our search for novel ways to prevent and treat inflammatory diseases.’

Marie was drawn to the Kennedy Institute by the opportunity to pursue translational research through NDORMS’s deeply phenotyped patient cohorts and ongoing translational initiatives. ‘Working with experts across the disciplines, from immunology and microbiology to physics, chemistry and computer science, all focused on translational output, alongside colleagues who work with patients every day, pushes my work towards the areas with the greatest clinical need and societal impact,’ she said. Another major draw was OCMS’s state-of-the-art microbiome infrastructure. ‘Starting my research group with this unique infrastructure, expertise and network already in place is a great privilege. I haven’t seen comparable microbiome resources anywhere else in Europe.’

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.

As NHS expands robotic surgery, Oxford research asks if it delivers better outcomes for hip and knee replacement operations

As the NHS prepares to substantially expand its use of robotic surgery, two major studies have found that robotic-assisted hip and knee replacement does not reduce the overall risk of repeat surgery compared with conventional surgery at five years – highlighting the importance of robust evidence as new surgical technologies are adopted at scale.